Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Point-of-Care CD4 Counter Evaluated

By LabMedica International staff writers
Posted on 10 Jan 2013
The measurement of the absolute CD4 T-cell count is critical in the initial evaluation and staging of persons infected human immunodeficiency virus (HIV). More...


However, access to the technology that allows for such measurements remains limited in many low resource settings where disease burden of HIV and acquired immunodeficiency disease syndrome (AIDS) is highest.

Scientists at MBio Diagnostics (Boulder, CO, USA) working with colleagues at the University of California (San Diego, CA, USA) evaluated the performance of a prototype point-of-care device (POC) to quantify CD4 T cells. The device combines single-use, disposable cartridges with a simple reader instrument. Based on the principle of static imaging cytometry with fluorescent immunostaining, the system utilizes a novel, laser-based illumination approach combined with MBio's proprietary planar waveguide technology.

A total of 94 participants provided venous whole blood samples and 52 capillary whole blood specimens. Study participants were HIV-infected individuals enrolled through a large primary HIV care program, at the University of California, San Diego between May 2011 and October 2011. Participants were predominantly male, of Caucasian and Hispanic race/ethnicity, with a median age of 44 years. The device, known as the Snapcount system, is a product of MBio Diagnostics and was compared with conventional flow cytometry (FACSCalibur, Becton Dickinson).

The prototype MBio system showed negligible quantitative bias relative to flow cytometry. Higher variability was observed in the capillary samples relative to venipuncture, but system precision was good for both capillary and venipuncture samples. There was also close agreement between results from the same participant when tested with two different systems, different operators, and different locations.

The authors wrote that developmental efforts are underway on a cartridge that incorporate lyophilized reagents and allows direct whole blood addition combined with a reader device. The reader device would include an integrated touch screen, internal and external quality control features, and data management software and network connectivity. The study was published in the January 2013 edition of the Journal of Immunological Methods.


Related Links:
MBio Diagnostics
University of California San Diego
Becton Dickinson


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.